163 are also involved in resistance to cisplatin, temozolomide and 5-fluorouracil via altering glycolysis in gastric cancer, glioblastoma and CRC, respectively. Interestingly, Fu et al reported that lncRNA plasmacytoma variant translocation 1 (PVT1) maintains Myc expression in Sjögren’s syndrome. This expression regulates proliferation and immune effects of CD4
+ T cells by controlling glycolytic metabolism.
164 Investigating the role of the PVT1-T cell glycolysis axis in tumor models may provide a novel insight for improving T cell-based immunotherapy.
The important role of lncRNAs-mediated glucose metabolic reprogramming in cancer adjuvant therapy, as discussed above, makes them promising targets for treating cancers. Several studies have revealed that siRNA, antisense oligonucleotides (ASOs) and clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) may be promising methods of targeting lncRNAs.
Apr. 1, 2021 , 10:10 AM
When New York City medical oncologist Vicky Makker meets a patient with endometrial cancer that has spread or recurred, she knows the outlook isn’t good. Even after radiation and drug treatments, most women with advanced disease die within 5 years.
But this spring, Makker is helping launch two clinical trials she hopes will change the picture. The drug patients will receive, called a phosphatidylinositol 3-kinase (PI3K) inhibitor, has already failed in multiple cancer trials. But the new studies are taking an unconventional tack to resurrect the drug: putting patients on a ketogenic diet, a low-carbohydrate regimen that typically involves loads of meat, cheese, eggs, and vegetables. The researchers hope the diet will render tumors more vulnerable to the drug, which blocks a growth-promoting pathway in cells. “It’s very outside of the mainstream thinking,” says Makker, a researcher at Memorial Sloan Kettering Cancer Center.
Publication Date: Description:
Prof. Matthew Vander Heiden has been selected to serve as the new director of MIT’s Koch Institute for Integrative Cancer Research, reports Anissa Gardizy for
The Boston Globe. “We have broken down all these barriers, these traditional silos of fields, and I think that uniquely positions us to answer the big questions about cancer going forward, says Vander Heiden of the Koch Institute s work.
Matthew Vander Heiden named director of the Koch Institute mit.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mit.edu Daily Mail and Mail on Sunday newspapers.
Menasha Superintendent Confident About Five-Day-a-Week School wtaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wtaq.com Daily Mail and Mail on Sunday newspapers.